| Bioactivity | MK-0952 is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 has the potential for Alzheimer’s disease study[1][2]. |
| In Vivo | MK-0952 (10 mg/kg) induces malaise in the rat[1]. |
| Name | MK-0952 |
| CAS | 934995-87-6 |
| Formula | C28H22FN3O4 |
| Molar Mass | 483.49 |
| Appearance | Solid |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
| Reference | [1]. Michel Gallant, et al. Discovery of MK-0952, a Selective PDE4 Inhibitor for the Treatment of Long-Term Memory Loss and Mild Cognitive Impairment. Epub 2010 Sep 21. [2]. Tingting Pan, et al. Dual Functional Cholinesterase and PDE4D Inhibitors for the Treatment of Alzheimer's Disease: Design, Synthesis and Evaluation of tacrine-pyrazolo[3,4-b]pyridine Hybrids. Behav Brain Res. 2016 Apr 15;303:26-33. |
MK-0952
CAS: 934995-87-6 F: C28H22FN3O4 W: 483.49
MK-0952 is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 has the potential for Alzheime
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.